Nexalis Therapeutics (ASX:NX1) OCF Margin %: 0.00% (As of Dec. 2025)


What is Nexalis Therapeutics OCF Margin %?

Nexalis Therapeutics ASX:NX1 OCF Margin % is 0.00% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Nexalis Therapeutics ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Nexalis Therapeutics's Cash Flow from Operations for the six months ended in Dec. 2025 was A$-0.93 Mil. Nexalis Therapeutics's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Nexalis Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Nexalis Therapeutics's current OCF Yield % is -19.50%.

The historical rank and industry rank for Nexalis Therapeutics's OCF Margin % or its related term are showing as below:


During the past 10 years, the highest OCF Margin % of Nexalis Therapeutics was -390.06%. The lowest was -8069.23%. And the median was -2361.03%.

ASX:NX1's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Nexalis Therapeutics OCF Margin % Related Terms

Nexalis Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Nexalis Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nexalis Therapeutics OCF Margin % Chart

Nexalis Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -688.02 -7,384.00 0.00 0.00 0.00

Nexalis Therapeutics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nexalis Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Nexalis Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-0.888/0
= %

Nexalis Therapeutics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.927/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Nexalis Therapeutics (ASX:NX1) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Nexalis Therapeutics and its competitors. According to the industry distribution chart, Nexalis Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Nexalis Therapeutics' OCF Margin % too high?
Nexalis Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Nexalis Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nexalis Therapeutics' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nexalis Therapeutics ranks #999999 out of 959 companies for OCF Margin %. This places Nexalis Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Nexalis Therapeutics and its competitors. Nexalis Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalis Therapeutics stock overvalued right now?
Nexalis Therapeutics (ASX:NX1) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Nexalis Therapeutics (ASX:NX1), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nexalis Therapeutics Business Description

Address 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.